Business Description
Turning Point Therapeutics Inc
NAICS : 325412
SIC : 2834
10628 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Description
Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 165.75 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 43.98 | |||||
| Beneish M-Score | -18.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -40.7 | |||||
| 3-Year EPS without NRI Growth Rate | -42.5 | |||||
| 3-Year FCF Growth Rate | -25.7 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 87.5 | |||||
| 9-Day RSI | 77.27 | |||||
| 14-Day RSI | 74.83 | |||||
| 6-1 Month Momentum % | 120.47 | |||||
| 12-1 Month Momentum % | 11.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 16.83 | |||||
| Quick Ratio | 16.83 | |||||
| Cash Ratio | 16.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.3 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -34185.81 | |||||
| Net Margin % | -33959.03 | |||||
| ROE % | -36.23 | |||||
| ROA % | -34.59 | |||||
| ROIC % | -1414.45 | |||||
| ROC (Joel Greenblatt) % | -3648.42 | |||||
| ROCE % | -36.39 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3800.5 | |||||
| PB Ratio | 4.78 | |||||
| Price-to-Tangible-Book | 4.78 | |||||
| EV-to-EBIT | -8.69 | |||||
| EV-to-EBITDA | -8.81 | |||||
| EV-to-Revenue | 2969.04 | |||||
| EV-to-Forward-Revenue | 6976.22 | |||||
| EV-to-FCF | -11.38 | |||||
| Price-to-Net-Current-Asset-Value | 4.85 | |||||
| Price-to-Net-Cash | 4.94 | |||||
| Earnings Yield (Greenblatt) % | -11.51 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:TPTX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.008 | ||
| EPS (TTM) ($) | -6.9 | ||
| Beta | -0.31 | ||
| Volatility % | 133.72 | ||
| 14-Day RSI | 74.83 | ||
| 14-Day ATR ($) | 0.525604 | ||
| 20-Day SMA ($) | 75.111 | ||
| 12-1 Month Momentum % | 11.85 | ||
| 52-Week Range ($) | 23.77 - 82.2 | ||
| Shares Outstanding (Mil) | 50.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Turning Point Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||